Track market-moving stories before they get noisy

Medtronic (MDT +0.83%) has raised its dividend payouts annually for 49 consecutive years. In other words, the medical device company is just one more year and one more hike away from becoming one of just a few dozen Dividend Kings -- publicly traded companies with at least 50 consecutive years of dividend growth.

However, this status alone may not necessarily indicate that it's a strong buy for income investors. Let's take a look at other factors to assess whether this dividend growth stock can produce the type of steady, solid total returns associated with such kingly status.

Image source: Getty Images

Dividend Kings status is well within reach for Medtronic If Medtronic raises its dividend again in June 2027, the company will officially attain Dividend King status. Based on the details, hitting this appears well within reach, if not a near certainty. For one, based on estimated earnings for the current fiscal year, Medtronic has a payout ratio of just 45%.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

0.83

%) $

0.77

Current Price

$

93.16

True, in March, Medtronic spun off its diabetes products business as a new public company, MiniMed Group (MMED -2.08%). For now, Medtronic holds around a 90% stake in MiniMed, but Medtronic CEO Geoff Martha says the company plans to eventually reduce that position to zero. However, don't assume this will severely affect Medtronic's dividend growth bandwidth once it happens.

It's still unclear whether Medtronic plans to complete the sale of that stock by the end of 2026, as it continues to include MiniMed's results in its full-year forecasts. Also note that MiniMed reported negative cash flow during the fiscal year that ended in April 2026. If Medtronic completes its divestiture of MiniMed while it remains unprofitable, it could increase Medtronic's overall cash flow, enabling a further dividend increase.

Not only that, on top of recent improving growth, forecasts call for a further growth resurgence. Finally, given that Medtronic has slowed the pace of its dividend growth in recent years, with the latest increase just 1.4%, it could easily implement another modest dividend increase next June without overextending itself, thereby clinching Dividend King status.

While Medtronic doesn't face any significant hurdles to becoming a Dividend King, it's unclear whether it is a strong choice for investors seeking portfolio income over price appreciation. If the company's anticipated growth resurgence pans out, it may lead to faster dividend growth in the coming years.

However, in the meantime, Medtronic may have to maintain its policy of low dividend growth to fund its main growth drivers, such as robotic surgery and cardiac products. Medtronic has also been making acquisitions, particularly of cardiac products companies, to boost growth. This, too, could limit how much Medtronic can devote to growing its quarterly cash payouts.

That said, for investors seeking both portfolio income and capital growth, it could be a solid opportunity in the coming years. For now, investors can collect a payout that yields about 3.1% at the current share price. In the years ahead, if earnings growth accelerates, shares could surge in line with earnings.

I wouldn't rule out the possibility of the market rerating the stock higher, but keep in mind that with Medtronic trading at around 15.5 times estimated earnings for the fiscal year ending April 2027, in line with other medical device stocks such as Boston Scientific and GE Healthcare, I wouldn't assume too much potential for multiple expansion.

California State Teachers Retirement System increased its holdings in Medtronic PLC (NYSE:MDT – Free Report) by 7,655.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 158,124,578 shares of the medical technology company’s stock after buying an additional 156,085,748 shares during the quarter. California State Teachers Retirement System owned 12.35% of Medtronic worth $12,370,086,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Monetary Solutions Ltd bought a new stake in shares of Medtronic during the 4th quarter valued at $27,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Medtronic in the 4th quarter worth $29,000. Imprint Wealth LLC bought a new position in Medtronic in the 3rd quarter worth $31,000. Basepoint Wealth LLC bought a new position in Medtronic in the 4th quarter worth $32,000. Finally, Tucker Asset Management LLC purchased a new position in Medtronic during the fourth quarter valued at $33,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In MDT has been the subject of several recent research reports. JPMorgan Chase & Co. cut their price target on Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday. The Goldman Sachs Group cut their price objective on Medtronic from $84.00 to $83.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Truist Financial reissued a “hold” rating and issued a $99.00 target price (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $92.00 target price on shares of Medtronic in a research note on Thursday, September 3rd. Nineteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $103.92.

Read Our Latest Stock Analysis on MDT Medtronic Stock Down 1.9% Shares of NYSE MDT opened at $92.41 on Wednesday. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The firm’s 50-day moving average price is $87.33 and its 200-day moving average price is $85.21. The stock has a market capitalization of $118.20 billion, a price-to-earnings ratio of 22.76, a P/E/G ratio of 2.21 and a beta of 0.56.

Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The company had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. During the same period in the previous year, the firm posted $1.26 earnings per share. The firm’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.96 EPS for the current fiscal year.

Medtronic Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s payout ratio is currently 70.94%.

Medtronic Profile (Free Report)

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.

See Also Five stocks we like better than Medtronic Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Even though major U.S. stock market indexes sit near all-time highs, it's possible to find beaten-down companies worth investing in. Consider Medtronic (MDT -1.89%) and MercadoLibre (MELI -2.63%), both leaders in their respective fields. These corporations have faced some challenges, but they remain excellent buy-and-hold options, despite lagging the market lately. Let me explain.

Image source: Getty Images.

1. Medtronic After spending most of the first half of the year moving south, Medtronic has been rebounding over the past three months. The company's financial results have something to do with that. Take the medical device specialist's first-quarter 2027 update for the period ended July 31. Medtronic’s revenue jumped 13.7% year over year -- a strong showing for the company -- to $9.8 billion. The healthcare leader's adjusted earnings per share (EPS) were $1.45, up 15.1% year over year. Medtronic also raised its revenue growth and EPS guidance for its full fiscal year 2027.

It was a beat-and-raise quarter for the company, which explains why its shares jumped after its earnings release. Still, Medtronic stock is down 2% year to date as of writing, while the S&P 500 has gained 12%. At current levels, the stock might be a steal, especially for investors focused on the long game. Medtronic is riding the wave of several growth drivers, will benefit from others in the medium term, and is also working to improve margins.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

-1.89

%) $

-1.78

Current Price

$

92.39

Right now, the company's cardiac ablation (a procedure that treats irregular heartbeats) solutions are doing much of the heavy lifting, thanks to innovative products it has launched in this niche in recent years. In the company's first quarter, cardiac ablation solutions revenue jumped 88% year over year.

Further, over the next few years, Medtronic should see its Hugo robotic-assisted surgery system gain traction and begin meaningfully contributing to its financial results, especially given the large addressable market in this field. And the company's planned separation of its diabetes care segment should help boost margins, since this unit has lower operating margins. Medtronic looks well-positioned to continue posting solid financial results while maintaining its dividend program.

The company has raised its payouts for 49 consecutive years, an impressive achievement that puts it close to joining the ranks of Dividend Kings, or corporations with at least 50 consecutive annual payout increases. Medtronic is an excellent buy-and-hold option for long-term income seekers.

2. MercadoLibre MercadoLibre has faced increased competition in the e-commerce market in South America. The company has responded by making significant investments in the business that are currently harming profits and margins. For instance, MercadoLibre has expanded free shipping offerings (by lowering the threshold for eligible transactions) in some markets. The e-commerce specialist is also doubling down on its fintech ambitions.

MercadoLibre is expanding credit card offerings across various regions, an initiative that is reducing net income due to expected credit loss provisions. In the second quarter, MercadoLibre's revenue grew by almost 50% year over year to $10.2 billion. But the company's EPS dropped to $9.19, down from the $10.31 reported in the year-ago period.

Despite the challenges -- and the reduced bottom line -- MercadoLibre is a great stock to buy. Here are three reasons why. First, MercadoLibre's initiatives, including expanded free shipping, have worked wonders for other e-commerce specialists by boosting gross merchandise volume and revenue. MercadoLibre has also benefited from similar efforts in the past, and its most recent attempts are already positively impacting financial results.

Premium Feature

Moneyball Superscore

86/100

Today's Change

(

-2.63

%) $

-52.11

Current Price

$

1,926.25

Second, the e-commerce leader's efforts should expand its ecosystem and competitive moat. MercadoLibre benefits from network effects and high switching costs. A larger pool of customers and merchants, combined with broader fintech offerings, can strengthen the company's moat. Third, there is a vast runway for growth in the markets where MercadoLibre operates. The company points out, for instance, that a substantial percentage of people in some of the regions where it does business are underbanked.

MercadoLibre will also benefit from the continued growth of the e-commerce market. The stock is down 18% over the past year, but the company's future seems bright. Investors should consider initiating a position before the stock bounces back.

Medtronic’s Stars Are Aligning for a Price RecoveryMedtronic NYSE: MDT executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.

Speaking at the Wells Fargo Healthcare Conference, Chairman and Chief Executive Officer Geoff Martha said medical technology is benefiting from innovations that can improve outcomes while potentially lowering costs and expanding patient access. He described AI and robotics as “force multipliers” that enable the company to diagnose conditions earlier and personalize treatment at scale.

Get Medtronic alerts:

Medtronic Bottoms, Healthy Rebound AheadMartha said Medtronic’s AI applications are centered on structured physiological, device and procedure data rather than broad large-language-model applications. He pointed to GI Genius, the company’s AI-supported colonoscopy technology, as an example. In the U.S., he said the technology is becoming a standard of care after clinical trials found that 25% to 50% of polyps could be missed even at leading centers. He also cited its use in India, where less-experienced physicians were able to achieve diagnostic results comparable to those in the U.S.

Limited ACA Exposure, China Stabilization Addressing concerns around healthcare policy changes, Martha said Medtronic has limited exposure to Affordable Care Act-related programs. He said the company’s procedure mix is largely acute rather than elective, with approximately two-thirds of its payer mix tied to Medicare, 25% to commercial insurance and less than 10% to Medicaid. ACA-related programs account for less than 1% of Medtronic’s global revenue, he said.

3 Reasons Analysts Love DexComIn China, Chief Financial Officer Thierry Piéton said Medtronic’s revenue exposure has fallen to between 5% and 6% following volume-based procurement, or VBP, changes. However, he said the company believes the impact of VBP is now largely behind it and that China has returned to a more normal operating environment. Martha said Medtronic remains committed to the country, which he characterized as a profitable growth market as the government expands access to higher-end healthcare.

First-Quarter Growth and Franchise Performance Piéton said Medtronic reported first-quarter growth of 13.7% including an extra week in the period, or about 7% after adjusting for that extra week. He said the company’s large established franchises are growing faster than in prior periods, while several newer businesses could provide additional expansion.

Cardiac rhythm management: Revenue rose 15% including the extra week, or about 9% on an adjusted basis, driven by EV-ICD, conduction system pacing and leadless pacemaker technology, according to Piéton. Spine: Piéton said the Stealth AXiS platform has helped Medtronic offer navigation, visualization and robotic-assistance tools alongside implants, supporting customer retention and pricing. Surgical: The surgical business performed well, including acute care and monitoring, he said. High-growth opportunities: Piéton identified cardiac ablation, Symplicity renal denervation for hypertension, Altaviva for urinary incontinence and Hugo surgical robotics as four potentially multibillion-dollar opportunities. Martha said Medtronic has effectively doubled its investment in innovation in recent years when both internal research and development and external investments, including venture investments and acquisitions, are considered. He said the company’s growth is diversified by geography, business line and a mix of organic and inorganic investment.

Cardiac Ablation and Robotics Expansion Cardiac ablation was a notable driver, with Martha describing the business as exceeding the company’s earlier expectation of reaching $2 billion in sales. Piéton said the market is growing at a mid-teens rate, or around 15%, and Medtronic expects to grow at more than 2.5 times the market rate for the full fiscal year. He said the company grew its capital-equipment installed base by 40% in the fourth quarter and by 35% sequentially in the first quarter, which should support future catheter demand.

Medtronic’s Sphere-9 catheter is currently a major contributor to ablation growth, Piéton said. The company has launched Sphere-360 in Europe and is conducting U.S. clinical trials. Martha said the company recently completed enrollment in the Sphere-360 trial, which includes a 12-month follow-up before submission.

On surgical robotics, Martha discussed Medtronic’s $700 million investment and distribution agreement with Cornerstone, which provides rights to the Sentire surgical robot in 50 countries outside the U.S. He said the deal broadens Medtronic’s offering in international markets, where hospitals and health systems may seek alternatives tailored to local needs and pricing.

Martha said Hugo, Medtronic’s surgical robotics platform, is focused on developed markets. The company expects to surpass 50,000 cumulative procedures and reach approximately 250 cumulative installed systems globally by year-end. Piéton said Hugo is already contributing to surgical-business growth, though the company did not provide specific revenue figures. Martha said Hugo has reached 99% uptime in the U.S. following software updates and refinements during its controlled launch.

Pipeline, Portfolio and Investor Day Martha said Medtronic sees renal denervation as a future billion-dollar product opportunity. He said the company is working to expand payer coverage and referral pathways for its hypertension therapy after a national U.S. coverage decision. He also said Medtronic plans more direct-to-consumer marketing in selected cities beginning in the fall.

Medtronic continues to evaluate tuck-in acquisitions, Piéton said, noting that the company has announced approximately $2.7 billion to $2.8 billion in deals over the last 12 months, compared with roughly $400 million to $500 million annually in the preceding six or seven years. He said the company intends to balance acquisition-related dilution with overhead leverage and improved gross margins.

The company also reiterated its intention to separate its MiniMed diabetes business. Piéton said Medtronic’s guidance assumes MiniMed remains consolidated for the full fiscal year, and that the ultimate earnings-per-share impact of a separation would depend on timing. He said MiniMed’s business performance has improved, but the intent to separate the business has not changed.

Medtronic plans to provide additional details on its growth outlook, new drivers and long-term financial framework at an Investor Day in December in Charlotte, North Carolina. Martha said the event will include demonstrations of the company’s robotics and digital technology ecosystems as well as physician perspectives.

About Medtronic (NYSE:MDT)Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Medtronic Right Now?Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

First Eagle Investment Management LLC raised its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 37.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,783,983 shares of the medical technology company’s stock after purchasing an additional 3,739,288 shares during the period. First Eagle Investment Management LLC owned about 1.08% of Medtronic worth $1,078,321,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. California State Teachers Retirement System boosted its holdings in shares of Medtronic by 7,655.7% during the second quarter. California State Teachers Retirement System now owns 158,124,578 shares of the medical technology company’s stock valued at $12,370,086,000 after acquiring an additional 156,085,748 shares during the period. BlackRock Inc. increased its holdings in shares of Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock worth $8,919,846,000 after acquiring an additional 838,220 shares during the period. State Street Corp increased its holdings in shares of Medtronic by 2.0% in the 4th quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock worth $5,966,780,000 after acquiring an additional 1,199,621 shares during the period. JPMorgan Chase & Co. lifted its position in Medtronic by 2.7% in the 4th quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock valued at $5,150,420,000 after purchasing an additional 1,419,730 shares during the last quarter. Finally, Capital Research Global Investors lifted its position in Medtronic by 12.6% in the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after purchasing an additional 3,880,174 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades Several research firms have commented on MDT. Rothschild & Co Redburn decreased their target price on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Weiss Ratings raised Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday. Royal Bank Of Canada reiterated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research report on Wednesday, September 2nd. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Evercore set a $105.00 price objective on Medtronic in a research note on Monday, July 6th. Nineteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $103.92.

Read Our Latest Stock Report on Medtronic Key Stories Impacting Medtronic Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic said executives will present at the Wells Fargo Healthcare Conference on September 8 and other upcoming investor events. These appearances could provide additional updates on growth initiatives, product launches, and financial guidance. Medtronic executives to speak at upcoming investor conferences Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating, while Stifel Nicolaus, Robert W. Baird, TD Cowen, and BTIG Research maintained bullish assessments or projected meaningful price appreciation. The broad analyst support reinforces investor confidence in MDT’s outlook. Royal Bank of Canada reaffirms Outperform rating Positive Sentiment: New real-world evidence from Medtronic’s PERSIST addendum study is supporting the company’s Inceptiv spinal cord stimulation system. Further clinical validation could improve adoption prospects and strengthen the pain-management franchise. Medtronic’s PERSIST study builds real-world evidence Positive Sentiment: Medtronic’s latest reported quarter exceeded expectations, with earnings of $1.45 per share versus a $1.39 consensus estimate and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, providing a favorable fundamental backdrop. Neutral Sentiment: Unusually large options trading indicates elevated investor interest in MDT, but the activity does not by itself establish whether traders expect further gains or a pullback. Medtronic target of unusually large options trading Negative Sentiment: A MarketWatch strategy highlighted Medtronic as a healthcare stock that may be overcrowded, recommending a bearish options position because many investors have already bet on additional gains. This raises the risk of profit-taking or volatility despite the positive fundamental and analyst backdrop. Healthcare stocks may be too crowded to own Medtronic Price Performance NYSE MDT opened at $94.12 on Monday. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $120.39 billion, a PE ratio of 23.18, a price-to-earnings-growth ratio of 2.21 and a beta of 0.56. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a 50 day moving average price of $86.78 and a two-hundred day moving average price of $85.27.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the prior year, the business posted $1.26 EPS. Medtronic’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.96 earnings per share for the current fiscal year.

Medtronic Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

About Medtronic (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Recommended Stories Five stocks we like better than Medtronic AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

/PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences:

Medtronic (MDT +0.50%), one of the world's largest medical device makers, was once considered a stable blue chip stock. But over the past five years, it has declined by more than 30% due to supply chain constraints, higher costs, quality control issues, and competitive pressure. However, Medtronic's stock is worth buying again for four simple reasons.

1. It's growing again In fiscal 2026 (which ended this April), Medtronic's revenue grew 8.4% (and 5.8% organically) to $36.4 billion, marking its strongest top-line growth in ten years.

Image source: Getty Images.

That acceleration was driven by 9.3% organic growth in its cardiovascular business, which accounted for more than 38% of its enterprise revenue. All of its other segments (neuroscience, medical surgical, and diabetes) also grew organically.

Medtronic expects its organic revenue to rise 7.25%-7.75% in fiscal 2027, representing another multi-year high and easily exceeding its historical average of around 5%. Once again, that growth will be led by its rising sales of cardiovascular devices. From fiscal 2026 to fiscal 2029, analysts expect its reported revenue to grow at a 5% CAGR.

Premium Feature

Moneyball Superscore

74/100

Today's Change

(

0.50

%) $

0.46

Current Price

$

92.64

2. Its cash flow is growing Medtronic has been restructuring its business to free up more cash to fund its dividends while expanding its higher-growth cardiovascular and neuroscience portfolios. Over the past year, it spun off its diabetes unit as MiniMed (MMED +0.46%), overhauled its cardiovascular business, pruned its workforce, and announced the closure of its Santa Rosa campus.

As a result, its free cash flow (FCF) grew 4.6% to $5.43 billion in fiscal 2026. It spent only $3.64 billion of that total on dividends, leaving ample room for future hikes.

3. It's a future Dividend King Medtronic pays a forward yield of 3.1%. It's raised its payout for 49 consecutive years, putting it on track to become a Dividend King if it crosses the 50-year mark next year.

4. It's still undervalued From fiscal 2026 to fiscal 2029, analysts expect Medtronic's EPS to grow at a 14% CAGR. But at $92, its stock trades at just 18 times next year's earnings. That makes it much cheaper than many of its industry peers and the S&P 500 -- which trades at 21 times forward earnings.

Medtronic isn't an exciting stock, but it's overcome most of its prior challenges and should grow again as it expands its cardiovascular and neuroscience businesses. Only a handful of companies can match Medtronic's scale and diversification, so it's still a reliable long-term play for investors who want an income-generating stock with a wide moat.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Medtronic (MDT - Free Report) Medtronic plc was formed after Medtronic, Inc., the legacy NYSE-listed parent company incorporated in Minnesota, acquired Ireland-based Covidien plc for cash and stock of $49.9 billion in 2015. The transaction created a new holding company incorporated in Ireland, which became the NYSE-listed parent company for both legacy businesses.

MDT is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. MDT has a Growth Style Score of B, forecasting year-over-year earnings growth of 7.6% for the current fiscal year.

Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2027. The Zacks Consensus Estimate has increased $0.01 to $5.95 per share. MDT boasts an average earnings surprise of +2.8%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MDT should be on investors' short list.

Medtronic PLC (NYSE:MDT) on Tuesday reported better-than-expected first-quarter financial results and raised its FY27 adjusted EPS guidance.

Medtronic reported quarterly earnings of $1.45 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $9.756 billion which beat the analyst consensus estimate of $9.545 billion.

Medtronic raised its fiscal 2027 adjusted earnings guidance from $5.90-$6 per share to $5.94-$6 per share. The new range compares with the $5.95 consensus estimate. The company also lifted its organic revenue growth forecast to 7.25% to 7.75%, up from its previous range of 6.75% to 7.25%.

For the second quarter, Medtronic expects adjusted earnings of $1.32 to $1.34 per share. The midpoint falls below the consensus estimate of $1.34.

Also, the company announced a $700 million strategic partnership with Cornerstone Robotics to expand global access to its Sentire Surgical System in select non-U.S. markets.

Trending

“We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms,” said Geoff Martha, Medtronic chairman and chief executive officer. “Our execution, alongside our innovation engine, positions us to serve more patients and deliver durable growth. The strength of our portfolio and pipeline gives us confidence in the opportunities ahead.”

Medtronic shares fell 0.3% to $91.80 in pre-market trading.

These analysts made changes to their price targets on Medtronic following earnings announcement.

Baird analyst David Rescott maintained the stock with a Neutral and raised the price target from $91 to $100. Stifel analyst Rick Wise maintained the stock with a Hold and raised the price target from $80 to $95. Considering buying MDT stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Partnership expands Medtronic's robotic-assisted surgery portfolio to expand access globally and gives surgeons and health systems more choice and flexibility $700 million investment includes rights to distribute Cornerstone Robotics' Sentire™ surgical system in select markets outside the U.S. Sentire will be a strong complement to Medtronic's Hugo™ robotic-assisted surgery (RAS) system, creating a unique portfolio of robotic solutions , /PRNewswire/ -- Medtronic, a global leader in healthcare technology, today announced a strategic partnership with Cornerstone Robotics, an innovative surgical robotics company committed to advancing minimally invasive surgery and improving access to the latest surgical care worldwide. The approximately $700 million investment includes rights to distribute Cornerstone Robotics' Sentire™ surgical system in select markets outside the U.S. where the system is market approved.

Medtronic will distribute Sentire alongside its Hugo™ robotic-assisted surgery (RAS) system. Together with Medtronic's connected surgical ecosystem, the two complementary platforms will expand access to robotic-assisted surgery and offer surgeons and health systems more choice and flexible solutions designed to meet their diverse needs and reach more patients globally.

With global adoption of robotic-assisted surgery still in the single digits, the opportunity to expand access to advanced surgical care for patients, physicians and health systems around the world is significant. Expanded choice and access are critical drivers of the future of robotic assisted surgery. Through this partnership, Medtronic and Cornerstone Robotics are building a multi-port portfolio anchored by the Hugo RAS system and expanded by Sentire, giving customers meaningful flexibility across clinical settings, procedural needs, and economic models.

"Our strategy is focused on driving the next generation of minimally invasive surgery, one of our biggest growth opportunities," said Matt Anderson, senior vice president and president, Surgical, Medtronic. "Surgeons, health systems and markets have varying needs and preferences, which is why we are investing across robotic platforms, digital tools and platform-enhancing technologies. With Sentire complementing the Hugo RAS system, Medtronic will be the only company offering this two-platform portfolio combined with our surgical ecosystem—giving customers more access, more choice, and flexible solutions that fit their clinical and operational needs."

Building on Hugo's momentum
The partnership builds on the momentum of Medtronic's Hugo RAS system, which is now being used in more than 35 countries across six continents, including the United States, where it received FDA clearance within the last year. Procedure growth for the Hugo RAS system is currently more than two times the growth rate of the robotic surgery market, and total procedures are expected to exceed 50,000 globally by the end of Medtronic's fiscal year.

Medtronic will continue to innovate the capabilities of the Hugo RAS system, including ongoing software upgrades, real-time artificial intelligence across its digital ecosystem, integrated stapling, expanded instrumentation, and clinical indications. The modular, multi-quadrant platform is designed for a broad range of soft-tissue surgical procedures and combines wristed instruments, 3D visualization, and Touch Surgery™ ecosystem with dedicated support for robotics program optimization, service, and training.

Expanding Access Through Sentire Surgical System
The Sentire system's architecture and immersive console with dual-console capability offer a familiar configuration suited to varying surgeon preferences and clinical needs. Developed entirely in-house by Cornerstone Robotics, Sentire has completed multi-specialty clinical trials and received CE Mark in May 2026 for use in minimally invasive general, gynecologic, thoracic, and urologic surgical procedures in addition to its market approval in China and Singapore.

"Since the founding of Cornerstone Robotics, we have been steadfast in our commitment to innovation, excellence and clinical value," said Samuel Au, founder and CEO, Cornerstone Robotics. "We are confident physicians and patients alike will be the greatest beneficiaries of this partnership as we continue to expand access across this dynamic market."

Medtronic continues to invest across its surgical ecosystem to expand access to robotic-assisted solutions for operating rooms around the world. This partnership is another step in strengthening that connected ecosystem and advancing the company's commitment to improving the lives of patients through minimally invasive surgery.

Advisors
Morgan Stanley & Co. LLC is serving as exclusive financial advisor to Medtronic, and Cleary Gottlieb Steen & Hamilton LLP is serving as lead legal counsel. Kirkland & Ellis and Global Law Office are acting as legal counsel to Cornerstone Robotics.

About Cornerstone Robotics 
Cornerstone Robotics is an innovative surgical robotics company driven by the vision of leading medical innovations for a healthier world. It advances surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient globally. With three global R&D hubs and six business centers worldwide, the company has established a 30,000-square-meter manufacturing facility in China. Developed entirely in-house, the Sentire™* Surgical System has completed multi-specialty clinical trials and received market approval across China, the European Union and Singapore, advancing high-quality surgical care worldwide.

To find out more information, please visit our website at https://en.csrbtx.com/

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owner. All other brands are trademarks of a Medtronic company.

Contacts:
Justin Paquette
Public Relations
+1-612-271-7935

Ingrid Goldberg
Investor Relations
+1-763-505-2696

SOURCE Medtronic plc

The $25k Day Trading Barrier is Gone. It's Time to Put Your Capital to Work.

For years, the PDT rule put a major roadblock in front of active traders. The barrier is no longer standing in the way.

But having more freedom doesn't mean every trade is worth taking. 

With Dynamite Day Trading Signals, you'll receive up to 2 options trade alerts per week, each targeting 50%+ gains in a single session.

NO holding positions overnight.

NO waiting weeks for a trade to develop.

Just focused options trades designed to capitalize on opportunities as they emerge.

👉 Get Access to Dynamite Day Trading Signals

Geoff Martha, Medtronic CEO, joins 'Squawk on the Street' to discuss shares rising Tuesday after the company announced a $700 million investment in Cornerstone Robotics, a robotic surgical company.

Medtronic NYSE: MDT is a good buy in late 2026 because stars such as value, growth, guidance, partnerships, and dividends are aligning. They point to sustained outperformance and potential acceleration but, more importantly, to robust capital returns.

Medtronic Today

$92.66 +2.02 (+2.22%)

As of 01:22 PM Eastern

This is a fair market value price provided by Massive. Learn more.

$73.31▼

$106.333.11%

24.80

$99.79

While share buybacks are at token levels, barely enough to offset dilutive forces and reduce the share count, dividends are more substantial. The dividend is among the top reasons to buy this stock, yielding over 3% with shares near long-term lows. Additionally, MDT is just one increase away from being crowned Dividend King.

Get Medtronic alerts:

Dividend King status is more than just a fancy title. It is a hallmark for well-managed, foresightful companies that can withstand economic downturns, sustaining and growing capital returns over time. It attracts long-term, buy-and-hold institutional investors such as California’s State Retirement Fund, which holds a 12% stake in MDT.

Buy-and-hold and institutional investors help reduce market volatility, as they rarely sell on headlines alone, and underpin upswings when conditions are favorable. Based on institutional trends, including steady accumulation over the past two years and a spike in early Q3, conditions are favorable. Regarding volatility, MDT stock carries a low 0.5x beta, revealing it is only half as likely to move on macro news as the average S&P 500 company.

Medtronic’s Earnings Beat and Raised Guidance Signal More UpsideMedtronic posted a solid Q1 of its fiscal year 2027 (FY2027), with revenue up 13.7% to over $9.75 billion, outperforming guidance and the analysts' consensus by a solid margin, including the impact of a well-telegraphed extra week. Strength came from double-digit or near-double-digit gains across all segments, led by an 18.9% increase in Cardiovascular. Core franchises like Rhythm Management were solid, growing 15%, and were supported by newer businesses such as Ablation Solutions, which grew 80%. Other segments, such as Neurosciences, Medical/Surgical, and Diabetes, grew organically by 9.3%, 10.2%, and 14.9%, respectively.

Margin was another area of strength. The company widened its margin on a GAAP and adjusted basis, driving faster earnings improvement. Critical takeaways include the 14.9% increase in adjusted operating earnings, a 15.1% increase in adjusted earnings per share (EPS), and free cash flow more than doubling.

Guidance is a catalyst for higher share prices. The company not only outperformed in Q1 FY2027, but also expects those strengths to carry into the next quarter and the rest of the year. Management raised the revenue range by 50 basis points (bps) and the low end of the EPS range, putting the midpoint above the consensus forecast, and is likely being cautious. Momentum in key franchises, investments, and partnerships points to sustained strength, potential outperformance, and improved guidance in the coming quarters.

Analysts Reflect Confidence in MDT’s Outlook92nd Percentile

Moderate Buy

8.6% Upside

Healthy

Strong

0.89 Selling Shares

7.24%

See Full Analysis

Analysts are responding favorably to MDT’s earnings report, highlighting top- and bottom-line strength, guidance, and potential acceleration in upcoming quarters. The critical takeaway is that analyst trends, which include price target increases and upgrades ahead of the release, remain bullish and are strengthening.

The consensus price target forecasted about 10% upside ahead of the report, with the high-end of $120 another 20% higher, and high conviction in the Moderate Buy rating. MarketBeat tracks 27 analysts covering MDT, a substantial figure for a blue-chip healthcare stock.

This group rates it as a consensus Moderate Buy with 67% Buy-side bias and no Sell ratings logged. Conviction in this rating will likely continue to firm as the year progresses, with the high-end target moving higher.

Medtronic’s Growth Catalysts Could Fuel the Next Leg HigherThis year’s catalysts include investment in Pi-Cardia and a partnership with Cornerstone Robotics. Pi-Cardia expands the cardiovascular portfolio with an advanced, potentially life-saving device for heart valve replacement, while Cornerstone Robotics is the robotic surgery portfolio. Medtronic has a deal for international distribution of its Sentire System, providing hospitals with a choice alongside the Hugo system.

Medtronic’s stock price also responded favorably to the earnings news, rising by approximately 5% in early premarket trading. The move showed support at a cluster of moving averages, including the long-term 150-week and short-term 30-day exponential moving averages, which could serve as a launchpad for a rally. If the market follows through on this signal, MDT shares could retest the critical resistance target at the top of its existing range within weeks, if not days, and move to a fresh high before the next earnings report.

Medtronic’s biggest risk is cybersecurity. It experienced a major breach earlier this year, exposing sensitive personal information and giving hackers access to devices. The company says no health-related issues have arisen, but the event raises safety concerns and increases litigation risk.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Medtronic Right Now?Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tuesday.

Following the market opening Tuesday, the Dow traded down 0.58% to 52,876.43 while the NASDAQ dipped 1.40% to 26,001.27. The S&P 500 also fell, dropping, 0.68% to 7,633.51.

Leading and Lagging Sectors

Health care shares jumped by 1.7% on Tuesday.

In trading on Tuesday, consumer discretionary stocks fell by 1.7%.

Top Headline

Medtronic PLC (NYSE:MDT) shares gained around 5% on Tuesday after the company reported better-than-expected first-quarter financial results and raised its FY27 adjusted EPS guidance.

Medtronic reported quarterly earnings of $1.45 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $9.756 billion which beat the analyst consensus estimate of $9.545 billion.

Trending

Also, the company announced a $700 million strategic partnership with Cornerstone Robotics to expand global access to its Sentire Surgical System in select non-U.S. markets.

Equities Trading UP
           

bioAffinity Technologies Inc (NASDAQ:BIAF) shares shot up 66% to $7.59 after the company announced that it is advancing the potential application of its CyPath Lung Test. Shares of Fly-E Group Inc (NASDAQ:FLYE) got a boost, surging 45% to $1.99. Wetour Robotics Ltd (NASDAQ:WETO) shares were also up, gaining 50% to $8.21 after the company announced it released a development demonstration of Orchestra combining surface electromyography with first-person vision to capture richer human-hand data for robot learning. Equities Trading DOWN

Alumis Inc (NASDAQ:ALMS) shares dropped 50% to $10.86 after the company disclosed topline results from Envudeucitinib Phase 2b trial in Systemic Lupus Erythematosus (SLE). Shares of KALA BIO Inc (NASDAQ:KALA) were down 19% to $0.54. Kala Bio and Virotek announced a Letter of Intent to establish an exclusive U.S. distribution partnership for ophthalmology genetic testing program. Nocera Inc (NASDAQ:NCRA) was down, falling 21% to $2.23. Commodities

In commodity news, oil traded up 2.9% to $88.20 while gold traded down 2.3% at $4,376.60.

Silver traded down 3.2% to $64.875 on Tuesday, while copper fell 1.6% to $6.5795.

Euro zone

European shares were lower today. The eurozone’s STOXX 600 slipped 0.5%, while Spain’s IBEX 35 Index fell 0.7%, London’s FTSE 100 fell 0.6%, Germany’s DAX dipped 0.9%, while France’s CAC 40 fell 0.3%.

Asia Pacific Markets

Asian markets closed lower on Tuesday, with Japan’s Nikkei 225 falling 0.15%, Hong Kong’s Hang Seng index declining 0.93%, China’s Shanghai Composite declining 0.16% and India’s BSE Sensex falling 0.02%.

Economics

The US Logistics Managers’ Index declined for a second straight month to a reading of 66.6 in August from 68.9 in the previous month.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Medtronic (MDT - Free Report) reported $9.76 billion in revenue for the quarter ended July 2026, representing a year-over-year increase of 13.7%. EPS of $1.45 for the same period compares to $1.26 a year ago.

The reported revenue represents a surprise of +3.02% over the Zacks Consensus Estimate of $9.47 billion. With the consensus EPS estimate being $1.39, the EPS surprise was +4.32%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Medtronic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- U.S. Revenue: $4.91 billion compared to the $4.82 billion average estimate based on two analysts. The reported number represents a change of +16.2% year over year.Net Sales- International: $4.85 billion compared to the $4.69 billion average estimate based on two analysts.Net Sales- World Wide Revenue: $9.76 billion versus the four-analyst average estimate of $9.53 billion.Net Sales- World Wide Revenue- Neuroscience: $2.68 billion versus $2.67 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.Net Sales- World Wide Revenue- Cardiovascular: $3.93 billion compared to the $3.78 billion average estimate based on four analysts. The reported number represents a change of +19.5% year over year.Net Sales- World Wide Revenue- Other: $29 million compared to the $19.75 million average estimate based on four analysts. The reported number represents a change of -59.7% year over year.Net Sales- World Wide Revenue- Medical Surgical- Surgical & Endoscopy: $1.74 billion versus the three-analyst average estimate of $1.72 billion. The reported number represents a year-over-year change of +7.9%.Net Sales- World Wide Revenue- Medical Surgical: $2.28 billion compared to the $2.24 billion average estimate based on three analysts. The reported number represents a change of +9.4% year over year.Net Sales- World Wide Revenue- Neuroscience- Neuromodulation: $539 million versus $567.41 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.9% change.Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies: $1.37 billion versus $1.34 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies: $774 million versus $769.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.3% change.Net Sales- World Wide Revenue- Diabetes: $843 million versus the three-analyst average estimate of $829.71 million. The reported number represents a year-over-year change of +16.9%.View all Key Company Metrics for Medtronic here>>>

Shares of Medtronic have returned +4.6% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Strength across the company's largest franchises, new growth platforms, and recent portfolio investments support the long-term growth trajectory

, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2027 (FY27), which ended July 31, 2026.

Key Highlights

Revenue of $9.8 billion, increased 13.7% as reported and 13.7% organic, roughly 200 basis points above guidance midpoint GAAP diluted EPS of $1.14; non-GAAP diluted EPS of $1.45, ahead of guidance Raising FY27 organic revenue growth guidance 50 basis points to 7.25% to 7.75%, and FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00 Cardiovascular grew 18.9%, led by 15% growth in Cardiac Rhythm Management and 88% growth in Cardiac Ablation Solutions Announced expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias Announces strategic investment in Pi-Cardia, a pioneer in leaflet modification technology Neuroscience grew 9.3%, driven by 13% growth in Cranial and Spinal Technologies, including low-20s growth in enabling technology; Altaviva meaningfully contributed to 15% growth in Pelvic Health Medical Surgical reported strong performance, up 10.2%, led by 9% growth in Surgical and 14% growth in Acute Care & Monitoring Announces strategic partnership with Cornerstone Robotics to further expand global access to robotic-assisted surgery Announced FDA clearance for Touch Surgery™ Aide next generation computing platform  Completed acquisitions of Scientia Vascular and SPR Therapeutics, Inc. "We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms," said Geoff Martha, Medtronic chairman and chief executive officer. "Our execution, alongside our innovation engine, positions us to serve more patients and deliver durable growth. The strength of our portfolio and pipeline gives us confidence in the opportunities ahead."

Financial Results
Medtronic reported Q1 worldwide revenue of $9.756 billion, an increase of 13.7% as reported and 13.7% on an organic basis. The Q1 FY27 organic revenue growth comparison excludes:

Other revenue of $29 million in the current year versus $72 million in the prior year Revenue from the Dutch Obesity Clinic (NOK) divestiture with no revenue in the current year and $17 million in the prior year Scientia revenue of $14 million (closed June 12) and SPR Therapeutics revenue of $5 million in the current year (closed July 16) Foreign exchange benefit of $57 million on the remaining net sales Results were impacted by the extra fiscal week, which occurred in Medtronic's first quarter of FY27. The company estimates the impact of the extra week benefited Q1 organic growth by approximately $570 million. 

Q1 revenue included:

Cardiovascular Portfolio revenue of $3.927 billion increased 19.5% as reported and 18.9% organic, with high-20s increase in Electrophysiology Therapies, high-single digit increase in Interventional Cardiology Therapies, high-single digit increase in CardioVascular Surgery, and low-double digit increase in Peripheral Vascular Health, all on an organic basis Neuroscience Portfolio revenue of $2.678 billion increased 10.3% reported and 9.3% organic, with low-double digit increase in Cranial & Spinal Technologies, high-single digit increase in Specialty Therapies, and low-single digit increase in Neuromodulation, all on an organic basis Medical Surgical Portfolio revenue of $2.279 billion increased 10.0% as reported and 10.2% organic, with high-single digit increase in Surgical & Endoscopy, and mid-teens increase in Acute Care & Monitoring, all on an organic basis Diabetes business revenue of $843 million increased 16.9% as reported and 14.9% organic1 Q1 GAAP operating profit and operating margin were $1.764 billion and 18.1%, respectively, an increase of 22.1% and 120 basis points, respectively. As detailed in the financial schedules included at the end of the release, Q1 non-GAAP operating profit and operating margin were $2.316 billion and 23.7%, respectively, an increase of 14.9% and 10 basis points, respectively.

Q1 GAAP net income and diluted earnings per share (EPS) were $1.470 billion and $1.14, respectively, representing increases of 41.4% and 40.7%, respectively. As detailed in the financial schedules included at the end of this release, Q1 non-GAAP net income and non-GAAP diluted EPS were $1.860 billion and $1.45 respectively, representing increases of 14.4% and 15.1%, respectively. 

Guidance
The company today raised its FY27 organic revenue growth and EPS guidance. The company raised its FY27 organic revenue growth guidance to 7.25% to 7.75%, an increase from the prior guidance of 6.75% to 7.25%. The company also raised its FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00 versus the prior $5.90 to $6.00. This guidance includes an estimated neutral to 1% accretive impact from foreign currency exchange based on recent rates.

"We continue to make targeted investments in innovation, portfolio development, and commercial execution that will support sustainable long-term value creation," said Thierry Piéton, Medtronic chief financial officer. "The combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance."

Video Webcast Information
Medtronic will host a video webcast today, September 1, at 7:45 a.m. EST (6:45 a.m. CST) to provide information about its business for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Quarterly Earnings icon at investorrelations.medtronic.com, and this earnings release will be archived at news.medtronic.com. Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Past Events and Presentations link under the News & Events drop-down at investorrelations.medtronic.com.

Financial Schedules and Earnings Presentation
The first quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Quarterly Earnings link at investorrelations.medtronic.com. To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here. To view the earnings presentation, click here.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn.

FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, material acquisition and divestiture transactions, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

NON-GAAP FINANCIAL MEASURES
This press release contains guidance and financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. Certain information in this press release also includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material.

Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, revenue in the current and prior year reported as "Other", as well as significant acquisitions, divestitures, or other significant discrete items. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

FINANCIAL COMPARISONS
References to quarterly or annual figures increasing, decreasing, or remaining flat are in comparison to fiscal year 2026, and references to sequential changes are in comparison to the prior fiscal quarter. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis. References to organic revenue growth exclude the impact of foreign currency, first quarter revenue in the current and prior year reported as "Other", as well as significant acquisitions, divestitures, or other significant discrete items. 

TRANSACTION DETAILS
The separation of our Diabetes business has involved and is expected to be completed through a series of capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof. While a split-off is the company's current preferred separation structure, a final decision has not been reached at this time.

Contacts:
Justin Paquette 
Public Relations
+1-612-271-7935

Ingrid Goldberg
Investor Relations
+1-763-505-2696

____________________________________

1

The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed) due to MiniMed's financials being prepared on a carve out basis through the date of the company's initial public offering (IPO) and on a standalone basis post IPO. 

MEDTRONIC PLC

WORLDWIDE REVENUE(1)

(Unaudited)

FIRST QUARTER(2)

REPORTED

ORGANIC

(in millions)

FY27

FY26

Growth

Currency
Impact(7)

FY27(8)

FY26(8)

Growth

Cardiovascular(3)

$     3,927

$     3,285

19.5 %

$         21

$     3,906

$     3,285

18.9 %

Electrophysiology Therapies

2,218

1,712

29.5

8

2,210

1,712

29.1

Interventional Cardiology Therapies

894

834

7.2

6

889

834

6.5

CardioVascular Surgery

477

436

9.3

5

472

436

8.1

Peripheral Vascular Health

338

302

11.6

2

336

302

11.0

Neuroscience(3)

2,678

2,427

10.3

6

2,653

2,427

9.3

Cranial & Spinal Technologies

1,365

1,211

12.8

(2)

1,367

1,211

12.9

Specialty Therapies

774

702

10.2

6

754

702

7.4

Neuromodulation(3)

539

514

4.7

2

531

514

3.3

Medical Surgical(3)

2,279

2,073

10.0

15

2,265

2,056

10.2

Surgical & Endoscopy(3)

1,740

1,601

8.7

14

1,726

1,584

9.0

Acute Care & Monitoring

539

471

14.4

1

538

471

14.2

Total Reportable Segments

8,884

7,785

14.1

43

8,823

7,768

13.6

Diabetes(4)

843

721

16.9

14

829

721

14.9

Other(5)

29

72

NM(6)

—

—

—

—

TOTAL

$     9,756

$     8,578

13.7 %

$         57

$     9,652

$     8,489

13.7 %

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)

The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(2)

Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in reported first quarter results. While it is difficult to calculate the impact of the extra week, the Company estimates the extra week benefited first quarter organic growth by approximately $570 million.

(3)

In fiscal year 2027, the Cardiovascular Portfolio divisions transitioned from Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular to Electrophysiology Therapies, Interventional Cardiology Therapies, CardioVascular Surgery, and Peripheral Vascular Health. Additionally, there was a product line that moved from the Medical Surgical Portfolio in the Surgical & Endoscopy division to the Neuroscience Portfolio in the Neuromodulation division. Prior year net sales has been recast to conform to the current year presentation.

(4)

The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed). The Diabetes Business as reported by Medtronic is prepared on a different basis than standalone Medtronic due to MiniMed's financials being prepared on a carve out basis through the date of the company's initial public offering (IPO) and on a standalone basis post IPO.

(5)

Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, and adjustments to the Company's Italian payback accruals resulting from the June 30, 2025 Legislative Decree published by the Italian Government for years 2015 to 2018.

(6)

Not meaningful (NM).

(7)

The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

(8)

The three months ended July 31, 2026 excludes $104 million of revenue adjustments, including $29 million of inorganic revenue for the transition activity noted in (5), $14 million of inorganic revenue related to the Scientia Vascular (Scientia) acquisition in the Specialty Therapies division, $5 million of inorganic revenue related to the SPR Therapeutics, Inc. (SPR) acquisition in the Neuromodulation division, and $57 million of favorable currency impact on the remaining net sales. The three months ended July 25, 2025 excludes $89 million of revenue adjustments, including $33 million of inorganic revenue for the transition activity noted in (5), $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (5), and $17 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.

MEDTRONIC PLC

U.S. REVENUE(1)(2)

(Unaudited)

FIRST QUARTER(3)

REPORTED

ORGANIC

(in millions)

FY27

FY26

Growth

FY27(7)

FY26(7)

Growth

Cardiovascular(4)

$     1,853

$     1,479

25.3 %

$     1,853

$     1,479

25.3 %

Electrophysiology Therapies

1,177

834

41.2

1,177

834

41.2

Interventional Cardiology Therapies

294

296

(0.8)

294

296

(0.8)

CardioVascular Surgery

186

170

9.6

186

170

9.6

Peripheral Vascular Health

196

180

9.2

196

180

9.2

Neuroscience

1,813

1,624

11.7

1,795

1,624

10.5

Cranial & Spinal Technologies

1,016

890

14.1

1,016

890

14.1

Specialty Therapies

447

393

13.8

434

393

10.4

Neuromodulation

350

341

2.6

345

341

1.2

Medical Surgical

982

884

11.1

982

884

11.1

Surgical & Endoscopy

671

622

7.9

671

622

7.9

Acute Care & Monitoring

311

263

18.5

311

263

18.5

Total Reportable Segments

4,649

3,988

16.6

4,630

3,988

16.1

Diabetes(5)

240

217

10.6

240

217

10.6

Other(6)

17

20

(12.1)

—

—

—

TOTAL

$     4,906

$     4,224

16.1 %

$     4,870

$     4,205

15.8 %

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)

U.S. includes the United States and U.S. territories.

(2)

The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(3)

Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in reported first quarter results.

(4)

In fiscal year 2027, the Cardiovascular Portfolio divisions transitioned from Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular to Electrophysiology Therapies, Interventional Cardiology Therapies, CardioVascular Surgery, and Peripheral Vascular Health. Prior year net sales has been recast to conform to the current year presentation.

(5)

The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed). The Diabetes Business as reported by Medtronic is prepared on a different basis than standalone Medtronic due to MiniMed's financials being prepared on a carve out basis through the date of the company's initial public offering (IPO) and on a standalone basis post IPO.

(6)

Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested.

(7)

The three months ended July 31, 2026 excludes $36 million of revenue adjustments, including $17 million of inorganic revenue for the transition activity noted in (6), $14 million of inorganic revenue related to the Scientia acquisition in the Specialty Therapies division, and $5 million of inorganic revenue related to the SPR acquisition in the Neuromodulation division. The three months ended July 25, 2025 excludes $20 million of revenue adjustments, including $20 million of inorganic revenue for the transition activity noted in (6).

MEDTRONIC PLC

INTERNATIONAL REVENUE(1)

(Unaudited)

FIRST QUARTER(2)

REPORTED

ORGANIC

(in millions)

FY27

FY26

Growth

Currency
Impact(7)

FY27(8)

FY26(8)

Growth

Cardiovascular(3)

$     2,074

$     1,806

14.8 %

$         21

$     2,053

$     1,806

13.7 %

Electrophysiology Therapies

1,041

878

18.5

8

1,033

878

17.6

Interventional Cardiology Therapies

601

538

11.6

6

595

538

10.5

CardioVascular Surgery

291

266

9.2

5

285

266

7.2

Peripheral Vascular Health

142

123

15.3

2

140

123

13.7

Neuroscience(3)

864

803

7.6

6

858

803

6.8

Cranial & Spinal Technologies

349

320

9.0

(2)

351

320

9.5

Specialty Therapies

326

309

5.6

6

321

309

3.7

Neuromodulation(3)

189

174

8.9

2

186

174

7.4

Medical Surgical(3)

1,297

1,188

9.2

15

1,282

1,171

9.5

Surgical & Endoscopy(3)

1,070

980

9.2

14

1,055

963

9.6

Acute Care & Monitoring

228

209

9.2

1

227

209

8.8

Total Reportable Segments

4,236

3,797

11.5

43

4,193

3,780

10.9

Diabetes(4)

603

504

19.6

14

589

504

16.8

Other(5)

12

53

NM(6)

—

—

—

—

TOTAL

$     4,850

$     4,354

11.4 %

$         57

$     4,782

$     4,284

11.6 %

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)

The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(2)

Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in reported first quarter results.

(3)

In fiscal year 2027, the Cardiovascular Portfolio divisions transitioned from Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular to Electrophysiology Therapies, Interventional Cardiology Therapies, CardioVascular Surgery, and Peripheral Vascular Health. Additionally, there was a product line that moved from the Medical Surgical Portfolio in the Surgical & Endoscopy division to the Neuroscience Portfolio in the Neuromodulation division. Prior year net sales has been recast to conform to the current year presentation.

(4)

The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed). The Diabetes Business as reported by Medtronic is prepared on a different basis than standalone Medtronic due to MiniMed's financials being prepared on a carve out basis through the date of the company's initial public offering (IPO) and on a standalone basis post IPO.

(5)

Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, and adjustments to the Company's Italian payback accruals resulting from the June 30, 2025 Legislative Decree published by the Italian Government for years 2015 to 2018.

(6)

Not meaningful (NM).

(7)

The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

(8)

The three months ended July 31, 2026 excludes $68 million of revenue adjustments, including $12 million of inorganic revenue for the transition activity noted in (5) and $57 million of favorable currency impact on the remaining net sales. The three months ended July 25, 2025 excludes $70 million of revenue adjustments, including $14 million of inorganic revenue related to the transition activity noted in (5), $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (5), and $17 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.

MEDTRONIC PLC

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited) 

Three months ended

(in millions, except per share data)

July 31, 2026

July 25, 2025

Net sales

$              9,756

$              8,578

Costs and expenses:

Cost of products sold, excluding amortization of intangible assets

3,416

3,001

Research and development expense

771

726

Selling, general, and administrative expense

3,198

2,806

Amortization of intangible assets

412

459

Restructuring charges, net

72

45

Certain litigation charges, net

—

27

Other operating expense (income), net

123

70

Operating profit

1,764

1,445

Other non-operating expense (income), net

(190)

(33)

Interest expense, net

186

176

Income before income taxes

1,769

1,302

Income tax provision

289

255

Net income

1,479

1,047

Net income attributable to noncontrolling interests

(9)

(7)

Net income attributable to Medtronic

$              1,470

$              1,040

Basic earnings per share

$                1.15

$                0.81

Diluted earnings per share

$                1.14

$                0.81

Basic weighted average shares outstanding

1,279.8

1,281.6

Diluted weighted average shares outstanding

1,285.1

1,287.1

The data in the schedule above has been intentionally rounded to the nearest million.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS(1)

(Unaudited) 

Three months ended July 31, 2026

(in millions, except per share data)

Net
Sales

Cost of
Products
Sold

Gross
Margin
Percent

Operating
Profit

Operating
Profit
Percent

Income
Before
Income
Taxes

Net Income
attributable
to
Medtronic

Diluted
EPS

Effective
Tax Rate

GAAP

$  9,756

$   3,416

65.0 %

$     1,764

18.1 %

$    1,769

$       1,470

$     1.14

16.4 %

Non-GAAP Adjustments:

Amortization of intangible assets

—

—

—

412

4.2

412

337

0.26

18.2

Restructuring and associated costs(2)

—

(8)

0.1

89

0.9

89

70

0.05

21.2

Acquisition and divestiture-related items(3)

—

(11)

0.1

50

0.5

50

41

0.03

18.2

(Gain)/loss on minority investments(4)

—

—

—

—

—

(64)

(64)

(0.05)

(0.1)

Certain tax adjustments, net(5)

—

—

—

—

—

—

5

—

—

Non-GAAP

$  9,756

$   3,396

65.2 %

$     2,316

23.7 %

$    2,257

$       1,860

$     1.45

17.2 %

Currency impact

(57)

(21)

—

(27)

(0.1)

(0.02)

Currency Adjusted

$  9,699

$   3,375

65.2 %

$     2,290

23.6 %

$     1.43

Three months ended July 25, 2025

(in millions, except per share data)

Net
Sales

Cost of
Products
Sold

Gross
Margin
Percent

Operating
Profit

Operating
Profit
Percent

Income
Before
Income
Taxes

Net Income
attributable
to
Medtronic

Diluted
EPS

Effective
Tax Rate

GAAP

$  8,578

$   3,001

65.0 %

$     1,445

16.8 %

$    1,302

$       1,040

$     0.81

19.6 %

Non-GAAP Adjustments:

Amortization of intangible assets(6)

—

—

—

459

5.5

459

374

0.29

18.5

Restructuring and associated costs(2)

—

(16)

0.1

67

0.8

67

51

0.04

22.4

Acquisition and divestiture-related items(3)

—

(7)

—

58

0.7

58

48

0.04

17.2

Certain litigation charges, net

—

—

—

27

0.3

27

21

0.02

22.2

(Gain)/loss on minority investments(4)

—

—

—

—

—

113

107

0.08

6.2

Other(7)

(39)

—

(0.2)

(39)

(0.5)

(39)

(30)

(0.02)

20.5

Certain tax adjustments, net(5)

—

—

—

—

—

—

16

0.01

—

Non-GAAP

$  8,539

$   2,979

65.1 %

$     2,016

23.6 %

$    1,987

$       1,626

$     1.26

17.8 %

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)

The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.

(2)

The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.

(3)

The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. Exit of business-related charges primarily relate to the impending separation of the Diabetes Business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.  

(4)

We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

(5)

The net charges for the three months ended July 31, 2026 and July 25, 2025, primarily relate to amortization of previously established deferred tax assets arising from previous intercompany intellectual property transactions. The net charges for the three months ended July 31, 2026, were partially offset by the release of reserves for uncertain tax positions on prior period intercompany transactions.

(6)

The Company recognized $45 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio.

(7)

Reflects adjustments to the Company's Italian payback accruals resulting from the June 30, 2025 Legislative Decree published by the Italian government for years 2015 to 2018.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS(1)

(Unaudited) 

Three months ended July 31, 2026

(in millions)

Net Sales

SG&A
Expense

SG&A
Expense as
a % of Net
Sales

R&D
Expense

R&D
Expense
as a % of
Net Sales

Other
Operating
Expense
(Income),
net

Other
Operating
Exp./(Inc.),
net as a % of
Net Sales

Other Non-
Operating
Expense
(Income), net

GAAP

$      9,756

$     3,198

32.8 %

$       771

7.9 %

$         123

1.3 %

$          (190)

Non-GAAP Adjustments:

Restructuring and associated costs(2)

—

(10)

(0.1)

—

—

—

—

—

Acquisition and divestiture-related items(3)

—

(26)

(0.3)

—

—

(13)

(0.1)

—

(Gain)/loss on minority investments(4)

—

—

—

—

—

—

—

64

Non-GAAP

$      9,756

$     3,162

32.4 %

$       771

7.9 %

$         110

1.1 %

$          (127)

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

(2)

The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.

(3)

The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. Exit of business-related charges primarily relate to the impending separation of the Diabetes Business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.

(4)

We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS(1)

(Unaudited)

Three months ended

(in millions)

July 31, 2026

July 25, 2025

Net cash provided by operating activities

$                      1,793

$                      1,088

Additions to property, plant, and equipment

(503)

(504)

Free Cash Flow(2)

$                      1,290

$                        584

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

(2)

Free cash flow represents operating cash flows less property, plant, and equipment additions.

MEDTRONIC PLC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three months ended

(in millions)

July 31, 2026

July 25, 2025

Operating Activities:

Net income

$                1,479

$                1,047

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

729

748

Provision for credit losses

25

28

Deferred income taxes

127

167

Stock-based compensation

125

86

Other, net

(29)

159

Change in operating assets and liabilities, net of acquisitions and divestitures:

Accounts receivable, net

224

288

Inventories

(240)

(373)

Accounts payable and accrued liabilities

(531)

(598)

Other operating assets and liabilities

(118)

(464)

Net cash provided by operating activities

1,793

1,088

Investing Activities:

Acquisitions, net of cash acquired

(1,162)

—

Additions to property, plant, and equipment

(503)

(504)

Purchases of investments

(2,190)

(2,100)

Sales and maturities of investments

2,209

2,010

Other investing activities, net

26

(125)

Net cash used in investing activities

(1,619)

(719)

Financing Activities:

Change in current debt obligations, net

812

649

Payments on long-term debt

—

(1,162)

Dividends to shareholders

(921)

(910)

Issuance of ordinary shares

20

95

Repurchase of ordinary shares

(267)

(123)

Other financing activities, net

13

70

Net cash used in financing activities

(343)

(1,381)

Effect of exchange rate changes on cash and cash equivalents

(89)

67

Net change in cash and cash equivalents

(258)

(945)

Cash and cash equivalents at beginning of period

1,949

2,218

Cash and cash equivalents at end of period

$                1,691

$                1,273

Supplemental Cash Flow Information

Cash paid for:

  Income taxes

$                   199

$                   402

  Interest

83

81

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

SOURCE Medtronic plc

You are now leaving Barron's websiteBy clicking on the “Proceed” button below, you will be redirected to a third-party website owned and operated by Hong Kong Tiimoot Information Technology Co., Limited. (“HKT”), which is located in Hong Kong. That website operates independently from Barron's and Barron's does not control the website. The privacy practices of HKT are subject to its Privacy Statement, so please read it closely. We are not responsible for HKT's privacy or other data-related practices.

Výrobce zdravotnických zařízení Medtronic zveřejnil výsledky za první kvartál fiskálního roku 2027, který skončil 31. července 2026. Tržby i očištěný zisk na akcii překonaly odhady trhu a společnost zároveň zvýšila celoroční výhled organického růstu tržeb i zisku na akcii.

Výsledky společnosti Medtronic (MDT) za 1Q FY 2027   1Q FY 2027 Konsensus 1Q FY2027 1Q FY 2026 Tržby (mld. USD) 9,76 9,54 8,54 Čistý zisk (mld. USD) 1,86 -- 1,63 Očištěný zisk na akcii (EPS, USD/akcie) 1,45 1,39 1,26 Výsledky za 1Q Tržby v prvním kvartále vzrostly meziročně o 13,7 % na 9,76 mld. USD, na organické bázi rovněž o 13,7 %. Do čísel se promítl navíc jeden fiskální týden, jehož přínos k organickému růstu firma odhaduje přibližně na 570 mil. USD.

Očištěná hrubá marže zaznamenala meziroční růst o 10 bazických bodů na 65,2 %. Trh projektoval 64,8 %.

Tržby Medtronicu v 1Q FY 2027 dle segmentů
(v mld. USD) Segment Tržby Konsenzus Meziroční změna Kardiovaskulární 3,93 3,78 +19,5 % Neurověda

2,68 2,66 +10,3 % Lékařsko-chirurgický

2,28 2,25 +10,0 % Diabetologie 0,84 0,82 +16,9 % Tahounem zůstal kardiovaskulární segment, v němž divize Cardiac Ablation Solutions vzrostla o 88 %, v USA dokonce o 139 %, a meziročně získala 9procentních bodů amerického tržního podílu. Cardiac Rhythm Management přidal 15 % a divize Cranial & Spinal Technologies 13 %. Z hlediska regionů rostly tržby v USA organicky o 15,8 % na 4,91 mld. USD, mimo USA o 11,6 % na 4,85 mld. USD.

Očištěná provozní marže dosáhla 23,7 % oproti 23,6 % před rokem, přičemž odhad trhu činil 23,8 %.

V průběhu kvartálu Medtronic dokončil akvizice společností Scientia Vascular a SPR Therapeutics. Zároveň oznámil strategickou investici a distribuční dohodu se společností Cornerstone Robotics týkající se systému Sentire na vybraných trzích mimo USA.

Výhled Společnost zvýšila celoroční výhled a pro fiskální rok 2027 nyní očekává:

Organický růst tržeb o 7,25 až 7,75 %, tedy o 50 bazických bodů více než dosavadních 6,75 až 7,25 %. Očištěný zisk na akcii v rozmezí 5,94 až 6,00 USD oproti předchozím 5,90 až 6,00 USD. Odhad Wall Street byl na úrovni 5,96 USD. Výhled zahrnuje vliv měnových kurzů na zisk na akcii v rozmezí neutrálního dopadu až 1% přínosu, u tržeb naopak negativní dopad 50 až 150 mil. USD.

Výhled také nadále zahrnuje diabetologický segment po celý fiskální rok 2027. Oddělení tohoto byznysu chce společnost dokončit ještě před koncem fiskálního roku a po jeho realizaci výhled aktualizuje.

Komentář vedení „Fiskální rok 2027 jsme zahájili silně. Důvěru nám nedodává pouze samotná síla tohoto kvartálu, ale především šíře výkonnosti napříč našimi obchodními jednotkami a rostoucí příspěvek novějších růstových platforem,“ uvedl generální ředitel Geoff Martha. „Naše realizační schopnost spolu s inovačním motorem nám umožňuje pomáhat většímu počtu pacientů a dosahovat udržitelného růstu. Síla našeho portfolia a připravovaných inovací nám dodává jistotu ohledně příležitostí, které máme před sebou.“

„Nadále cíleně investujeme do inovací, rozvoje portfolia a obchodní realizace, což podpoří udržitelnou dlouhodobou tvorbu hodnoty,“ uvedl finanční ředitel Thierry Piéton. „Kombinace silné provozní výkonnosti a disciplinovaného finančního řízení dostala tržby i očištěný zisk na akcii nad očekávání, což nám umožnilo zvýšit výhled pro fiskální rok 2027.“

Akcie Medtronic Akcie Medtronic (MDT) v předburzovní fázi obchodování posilují o 5,01 % na 95,19 USD.

Michal Bárta, Fio banka, a.s.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Key Takeaways Medtronic expects Q1 growth across Cardiovascular, Neuroscience, MedSurg and Diabetes.MDT's Cardiovascular growth may be led by PFA momentum and strength in Cardiac Rhythm Management.MDT's MiniMed launches and sensor integrations are expected to boost Diabetes revenues. Medtronic plc (MDT - Free Report) is slated to report its first-quarter fiscal 2027 results on Sept. 1, before the opening bell.

The Zacks Consensus Estimate for the company’s first-quarter earnings per share (EPS) suggests 10.3% year-over-year growth to $1.39. The estimate has remained constant in the past 60 days. The consensus mark for first-quarter revenues currently stands at $9.47 billion, implying a 10.4% increase over the prior-year period. 

Image Source: Zacks Investment Research

Medtronic has a solid earnings surprise history, beating estimates in each of the past four quarters, with an average surprise of 2.3%.

Image Source: Zacks Investment Research

Q1 Earnings Whispers for MDTPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below.

Earnings ESP: Medtronic has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.

Factors Likely to Have Shaped MDT’s Q1 PerformanceCardiovascularThe segment is likely to have witnessed a solid performance across both U.S. and international markets. Within this, Cardiac Ablation Solutions (“CAS”) is expected to have remained the key growth driver, supported by momentum in the pulsed field ablation portfolio, which grew 145% in the previous quarter. The launch of the Sphere-9 catheter in Japan may have also strengthened Medtronic’s position in the region. 

The company has also begun the global rollout of Prism-2, its next-generation mapping software, which offers improved navigation through hybrid impedance and magnetic mapping. In June 2026, Medtronic announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies, which may have provided an additional boost to revenues. 

Cardiac Rhythm Management may also have contributed, driven by Micra leadless pacemakers, Aurora implantable cardioverter defibrillator (EV-ICD) system and the SelectSecure 3830 lead.

In Structural Heart, revenues are expected to have benefited from continued international strength as well as stabilizing U.S. procedure volumes. Growth in the Symplicity Spyral renal denervation system, guide catheters and balloons, as well as Endovenous growth in Peripheral Vascular Health, may have boosted Coronary & Peripheral Vascular sales.

The Zacks Consensus Estimate implies Cardiovascular revenues will increase 15.2% year over year.

NeuroscienceMedtronic continues to invest across its Neuroscience portfolio to advance pipeline innovation and support long-term growth. Within this, Cranial and Spinal Technologies results in the fiscal first quarter may benefit from the continued adoption of the AiBLE ecosystem, with Core Spine and Neurosurgery also likely contributing to growth. The commercial rollout of the Stealth AXiS surgical system may have further advanced. In June, Medtronic received the CE mark for the ear, nose and throat indications, expanding the platform’s reach.

Neuromodulation performance is expected to have been led by the Inceptiv closed-loop spinal cord stimulator, the Percept RC neurostimulator with BrainSense technology, and Interventional products.

Medtronic completed two acquisitions within this business. The Scientia Vascular acquisition in June adds a portfolio of guidewires and catheters to its existing neurovascular product lineup, while the July acquisition of SPR Therapeutics, Inc. (SPR) expands its ability to serve patients across the pain care continuum.

The Zacks Consensus Estimate expects Neuroscience revenues to grow 10.7% year over year.

Medical Surgical (MedSurg)In the fiscal first quarter, MedSurg performance is expected to have been driven by solid growth in Advanced Energy and Wound Management, alongside higher contribution from the Hugo robotic-assisted surgery system. However, similar to recent trends, continued pressure on U.S. bariatric surgery procedure volumes may have partially offset this growth.

Endoscopy is likely to have been a growth driver, with sales benefiting from strong adoption of Endoflip in the United States and Western Europe, as well as from U.S. market share gains of the Nexpowder hemostasis system. Acute Care and Monitoring may have gained from strength in Nellcor pulse oximetry, respiratory and airways and in perioperative.

The Zacks Consensus Estimate for MedSurg’s revenues suggests a 7.6% year-over-year increase.

DiabetesMiniMed, Medtronic’s diabetes business, completed an initial public offering in March, with approximately 10% of its ownership sold and its shares beginning to trade on the Nasdaq Global Select Market. Medtronic continues to hold approximately 90% ownership in MiniMed.

In the first quarter of fiscal 2027, the business is likely to have witnessed robust international contributions from the continued adoption of the MiniMed 780G Automated Insulin Delivery (AID) system, including the Simplera Sync and Guardian 4 continuous glucose monitoring sensors and Extended Infusion Sets. U.S. momentum may also have continued following the late-2025 launches of the Simplera Sync and Abbott’s Instinct sensors. 

The quarter also saw several key developments. MiniMed announced the commercial availability of MiniMed Flex, its smallest app-controlled insulin pump powered by the advanced SmartGuard algorithm. The system is FDA cleared for people with type 1 diabetes aged 7 years and older, as well as adults aged 18 years and older with insulin-requiring type 2 diabetes and is paired with the Simplera Sync sensor. MiniMed Flex is also now available to Medicare and Medicare Advantage beneficiaries.

MiniMed launched the MiniMed 780G system integrated with Abbott’s Instinct sensor and the MiniMed Go system with the Instinct Go sensor in Europe. Together, these developments are expected to have strongly boosted overall revenues in the quarter.

The Zacks Consensus Estimate suggests Diabetes revenues will grow 15.1% year over year.

MDT Stock Price PerformanceOver the past three months, Medtronic shares have outperformed the industry and the broader Medical sector.

Image Source: Zacks Investment Research

The stock has also fared better than major peers like Boston Scientific (BSX - Free Report) , whose shares fell 2%, while Edward Lifesciences (EW - Free Report) gained 4.8%. Boston Scientific’s second-quarter 2026 revenues and EPS surpassed the Zacks Consensus Estimate by 1.1% and 3.6%, respectively. However, the company lowered its 2026 sales and earnings outlook after slower WATCHMAN demand, U.S. electrophysiology share losses and limited operating leverage weakened near-term visibility. Meanwhile, Edwards’ second-quarter revenues and EPS topped the consensus mark by 2.4% and 6.8%, respectively.

MDT’s ValuationMedtronic trades at a forward five-year Price/Earnings (P/E) of 14.98X, lower than its median of 15.73X and the industry average of 17.74X.

Image Source: Zacks Investment Research

EndnoteMedtronic’s upcoming fiscal first-quarter results are expected to reflect ongoing momentum in CAS, as well as strength in businesses such as Cardiac Rhythm Management and Cranial and Spinal Technologies. At the same time, the company is also advancing its M&A and venture initiatives, targeting higher-growth segments to accelerate innovation.

While current indicators do not point to a strong earnings beat, the company has a consistent earnings surprise history, which is encouraging. Medtronic’s recent stock performance has been impressive, outpacing the key benchmarks and peers. Existing MDT shareholders should consider holding their positions, supported by the company’s attractive valuation.  

The upcoming report from Medtronic (MDT - Free Report) is expected to reveal quarterly earnings of $1.39 per share, indicating an increase of 10.3% compared to the year-ago period. Analysts forecast revenues of $9.47 billion, representing an increase of 10.4% year over year.

The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

Given this perspective, it's time to examine the average forecasts of specific Medtronic metrics that are routinely monitored and predicted by Wall Street analysts.

The average prediction of analysts places 'Net Sales- World Wide Revenue- Other' at $19.75 million. The estimate indicates a change of -72.6% from the prior-year quarter.

It is projected by analysts that the 'Net Sales- World Wide Revenue- Neuroscience' will reach $2.67 billion. The estimate suggests a change of +10.7% year over year.

The combined assessment of analysts suggests that 'Net Sales- World Wide Revenue- Cardiovascular' will likely reach $3.78 billion. The estimate suggests a change of +15.2% year over year.

Analysts forecast 'Net Sales- World Wide Revenue- Medical Surgical' to reach $2.24 billion. The estimate points to a change of +7.6% from the year-ago quarter.

Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Diabetes' should arrive at $829.71 million. The estimate indicates a year-over-year change of +15.1%.

The collective assessment of analysts points to an estimated 'Net Sales- World Wide Revenue- Cardiovascular- Structural Heart & Aortic' of $993.59 million. The estimate points to a change of +6.8% from the year-ago quarter.

According to the collective judgment of analysts, 'Net Sales- World Wide Revenue- Medical Surgical- Surgical & Endoscopy' should come in at $1.72 billion. The estimate suggests a change of +6.8% year over year.

Analysts expect 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' to come in at $567.41 million. The estimate points to a change of +12.6% from the year-ago quarter.

Analysts predict that the 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' will reach $1.34 billion. The estimate indicates a change of +10.7% from the prior-year quarter.

Analysts' assessment points toward 'Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular' reaching $714.07 million. The estimate points to a change of +11.1% from the year-ago quarter.

The consensus estimate for 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' stands at $769.31 million. The estimate points to a change of +9.6% from the year-ago quarter.

The consensus among analysts is that 'Net Sales- U.S. Revenue' will reach $4.82 billion. The estimate indicates a year-over-year change of +14.1%.

View all Key Company Metrics for Medtronic here>>>

Shares of Medtronic have demonstrated returns of +5.1% over the past month compared to the Zacks S&P 500 composite's +3.7% change. With a Zacks Rank #3 (Hold), MDT is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Key Takeaways Medtronic's Cardiovascular business grew 9.3% organically in fiscal 2026, led by strong rhythm growth.MDT's Hypertension momentum builds as Symplicity Spyral gains access and procedures double after the NCD.Medtronic faces tariff costs and currency risks, with fiscal 2027 guidance signalling a revenue drag. Medtronic plc (MDT - Free Report) is well-poised for growth in the upcoming quarters due to strong momentum in its Cardiovascular businesses, both in the United States and internationally. In Neuroscience, the company is investing across the portfolio to advance pipeline innovation and long-term growth. Medtronic’s Hypertension business could benefit from a large unmet need as renal denervation moves into broader use. Yet, macroeconomic pressures and adverse foreign exchange impacts may weigh on the company’s results.

Over the past year, this Zacks Rank #3 (Hold) stock has gained 0.1% against the industry’s 23.1% decline and the S&P 500 composite’s 20.2% rise.

The renowned medical device company has a market capitalization of $116.67 billion. Medtronic has an earnings yield of 6.5% compared with the industry’s yield of 2.6%. MDT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.3%.

Let’s delve deeper.

Tailwinds for MDTMarket Share Gain Within Cardiovascular to Continue: Medtronic is expanding its global foothold within the Cardiovascular business. Fiscal 2026 Cardiovascular revenues grew 9.3% organically, while fourth-quarter revenues rose 10.1% organically, led by 18.2% growth in Cardiac Rhythm & Heart Failure. Cardiac Ablation Solutions delivered 78% growth, including 124% growth in the United States, and gained 8 U.S. share points.

Cardiac Rhythm Management grew in the mid-single digits, supported by Micra, the SelectSecure 3830 lead, Aurora EV-ICD and OmniaSecure. Peripheral Vascular Health also benefits from the full market release of Liberant mechanical thrombectomy and Neuroguard IEP carotid stenting. These platforms support continued share capture across several cardiovascular categories, while fiscal 2027 commentary calls for Cardiovascular performance broadly in line with fiscal 2026.

Image Source: Zacks Investment Research

Neuroscience Portfolio Shows Growth Prospects: Medtronic’s Neuroscience portfolio remains broad, with growth opportunities across Cranial & Spinal Technologies, Specialty Therapies and Neuromodulation. Fiscal 2026 Neuroscience revenues rose 3.1% organically, and fourth-quarter growth was 3% organically, led by 6% growth in international markets. Within CST, Core Spine grew 6% in the fourth quarter, supported by ModuleX expansion and distributor conversions.

Stealth AXiS secured FDA clearance for spine, cranial and ENT indications and CE Mark for spine and cranial indications, which broadens the platform’s contribution to AiBLE. Specialty Therapies grew 3.4% organically in the fourth quarter, while Neurovascular rose 6% as hemorrhagic products advanced 11% with Neuroguard and Artisse adoption. In Pelvic Health, Altaviva is gaining traction, with active implanters up threefold sequentially and patients treated up 2.5 times. In Neuromodulation, SPR Therapeutics and ViaVerte expand Medtronic’s reach into chronic pain therapies and BVNA.

Hypertension, A New Focus Area: Medtronic’s Hypertension business is entering a broader commercial ramp-up through the Symplicity Spyral renal denervation procedure. The final Medicare National Coverage Determination enabled broader access, and procedure momentum improved after reimbursement clarity. Management noted that average weekly procedures doubled after the NCD, and Symplicity is now annualizing at $100 million.

The company estimates roughly 18 million people in the United States live with uncontrolled hypertension despite multiple medications. Long-term data in more than 2,000 patients showed sustained mean systolic BP reductions of 13.3 millimeters of mercury in ambulatory settings and 18.1 millimeters of mercury in office settings in three years. This evidence, combined with expanding reimbursement and patient demand, supports management’s view that renal denervation can become a multi-billion-dollar opportunity over time.

Downsides for MDTMacroeconomic Issues Hamper Market Growth: Medtronic’s operations remain vulnerable to cost inflation, reimbursement constraints, geopolitical disruption and changing global trade policies. Tariffs impacted the business by 80 basis points (bps) in the fourth quarter of fiscal 2026 after a 110 bps impact in the third quarter. For fiscal 2027, management expects tariff impact on the cost of goods sold (COGS) of approximately $250 million, up $65 million year over year, with no government refund assumed.

Exposure to Currency Movement: Medtronic generates a large portion of sales internationally, leaving reported results sensitive to exchange rates. Foreign exchange added $819 million to fiscal 2026 revenues, but fiscal 2027 guidance assumes a neutral to $100 million revenue drag.

MDT Stock Estimate TrendThe Zacks Consensus Estimate for Medtronic’s fiscal 2027 earnings per share (EPS) has remained constant at $5.94 in the past 30 days.

The consensus estimate for the company’s fiscal 2027 revenues is pegged at $38.64 billion, implying a 6.3% increase from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .

Globus Medical has an earnings yield of 5.8% compared to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 35.1% against the industry’s 3.5% decline over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 47.8% against the industry’s 3.5% plunge. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have rallied 9.9% against the industry’s 3.5% fall over the past year.

Ally Financial Inc. acquired a new position in shares of Medtronic PLC (NYSE:MDT – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 44,000 shares of the medical technology company’s stock, valued at approximately $3,442,000.

A number of other institutional investors and hedge funds have also bought and sold shares of MDT. Norges Bank acquired a new stake in Medtronic during the 4th quarter worth approximately $1,653,485,000. WCM Investment Management LLC acquired a new position in Medtronic in the 1st quarter valued at approximately $965,922,000. Capital Research Global Investors increased its position in Medtronic by 12.6% in the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after acquiring an additional 3,880,174 shares during the period. Wellington Management Group LLP raised its stake in shares of Medtronic by 35.3% during the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock valued at $970,456,000 after acquiring an additional 2,658,981 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Medtronic by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after acquiring an additional 1,888,381 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth A number of equities analysts have recently commented on the stock. TD Cowen cut their price target on shares of Medtronic from $119.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. The Goldman Sachs Group lowered their target price on Medtronic from $84.00 to $83.00 and set a “neutral” rating for the company in a research report on Thursday, June 4th. UBS Group raised Medtronic from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $85.00 to $100.00 in a report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. reduced their price target on Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $98.83.

Check Out Our Latest Stock Analysis on Medtronic Medtronic Price Performance Shares of NYSE MDT opened at $93.44 on Monday. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The firm has a fifty day simple moving average of $84.39 and a 200 day simple moving average of $85.94. The company has a market capitalization of $119.60 billion, a PE ratio of 25.05, a P/E/G ratio of 2.50 and a beta of 0.55. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52.

Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.01. The business had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. Medtronic’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, sell-side analysts forecast that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s payout ratio is currently 77.21%.

Insider Activity In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is owned by corporate insiders.

About Medtronic (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Featured Stories Five stocks we like better than Medtronic VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

1.27K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: All research, figures, and interpretation are provided on a best-effort basis only and may be subject to error. Any view, opinion, or analysis does not constitute as investment or trading advice; please do your own due diligence.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 20, 2026, approved the company's cash dividend for the second quarter of fiscal year 2027 of $0.72 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in June 2026. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 49 consecutive years. The dividend is payable on October 16, 2026, to shareholders of record at the close of business on September 25, 2026.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Justin Paquette
Public Relations
+1-612-271-7935 

Ingrid Goldberg
Investor Relations  
+1-763-505-2696

SOURCE Medtronic plc